Skip to main content

Table 3 Recent studies on curcumin treatment for ovarian cancer

From: Therapeutic role of curcumin and its novel formulations in gynecological cancers

Type of curcumin Dose Main target (s) Main effect (s) Model (in vivo/in vitro/human) Cell line Ref
Curcumin 20 μM for
96 hours
Wnt/β-catenin Inhibition of tumor growth, migration, and invasion
Inhibition of epithelial-mesenchymal transition
Inhibition of autophagy
Induction of apoptosis
Increased the sensitivity of cancer cells
Induced cell cycle arrest
Antioxidant and anti-proliferative effects
In vitro SKOV3 [113]
20 μM for
48 hours
- In vitro ES2, OVCAR3 [114]
30, 40 μM for
48 hours
AKT/mTOR/p70S6K In vitro SK-OV-3, A2780 [104]
400 μM NQO1, c-Myc, Cyclin B1, Cyclin D1 In vitro OVCAR3, OVCAR5, SKOV3 [115]
20 μM FAK In vitro SKOV-3, OVCAR-3, PA-1 [116]
25.8, 53.0 mg/day NF-κB In vivo - [117]
Dose: 20 mg/kg (In vivo)
Dose: 10 μM for 48 hours
miR-124 In vitro
In vivo
SKOV3 [118]
1 μM for 36 hours miR-214, MEG3 In vitro A2780
60 μM for 72 hours - In vitro SKOV3 [119]
50 μM MMP-9, CD44, osteopontin In vitro SKOV3 [120]
10 μM for 2 and 3 hours STAT3, IL-6, IL-8 In vitro PA-1, OVCAR-3 [121]
80 μM for 24 hours Caspase-3, PARP-1, Bcl-2, P13K/Akt, P38 MAPK In vitro HEY, OVCA429, OCC1, SKOV3 [22]
50 μM for 240 min Caspase-3, IL-6, STAT-3, p-JAK-1 and p-JAK-2, PIAS-3, SOCS-3 In vitro OVCA420, OVCA429 [36]
40 μM for 24 hours AQP-3 In vitro CaOV3 [108]
0.5 μM for 48 hours ROS, glutathione In vitro C13, 2008 [122]
50μM for 24 hours AMPK, p38, p53 In vitro CaOV3 [123]
40μM for 72 hours PI3K/Akt In vitro SKOV3 [124]
60μM ALDH1A1 In vitro SKOV3
15μM for 24 hours SERCA In vitro MDAH 2774, SKOV3, PA1 [105]
41.6μmol/L for 12 hours Bcl-2, p53, MDM2, NFκB, caspase-3 In vitro A2780 [125]
3 μM for 12 hours Rho A/Rho-kinase In vitro SKOV3 [126]
40μM for 48 hours Bcl-2, Bcl-xL, caspase-3, p53, Bax In vitro HO-8910 [106]
Curcumin-loaded biodegradable PLGA nanoparticles (CUR-NP) 0.1 mg/mL
50 μM
- CUR-NP exhibited better physicochemical properties compared to free curcumin In vitro SK-OV-3 [127]
Curcumin-coated silver nanoparticles (cAgNPs) 2μg/mL for 48 hours Caspase 3/9, p53, MPP-9 Apoptosis induction In vitro A2780 [128]
Combinational polymeric micelles for co-delivery of quercetin/resveratrol and resveratrol/curcumin 1 mg/ml Caspase-3 Apoptosis induction In vitro
In vivo
ES2-Luc, A2780ADR [129]
DNC 55 μM for 48 hours LSINCT5, CCAT2, ABO73614, ANRIL, FAL1, BC200, MALAT1 Apoptosis induction
Inhibited tumor growth
In vitro OVCAR3
Curcumin-loaded PLGA MPs Dose: 20 and 40μM for 48 and 72 hours
Dose: 100 mg/kg (In vivo)
- CPMs formulation was more effective than free curcumin in suppressing proliferation of ovarian cancer cells In vitro
In vivo
SKOV-3 [131]
Curcumin nanoparticle 50 μg/ml P-gp Decreased chemotherapy resistance
Induced cell cycle arrest
Apoptosis induction
Antioxidant effects
In vitro A2780 [132]
6.62 μg/mL HSP70 In vitro
In vivo
SKOV3 [133]
Difluorinated curcumin
Folate decorated bovine serum albumin
(FA-BSA) nanoparticles loaded with Difluorinated curcumin
162.8 nM - Apoptosis induction In vitro SKOV3 [85]
FA-SMA-CDF nanomicelles 1.55 ± 0.23 μM for 72 hours PTEN, NFκB, Apoptosis induction In vitro SKOV3 [89]
Demethoxycurcumin 20, 40 and 80 μM for 48 hours IRS2/PI3K/Akt
Anti-proliferative effects
Apoptosis induction
In vitro ES2, HO8640, HO8640PM, SKOV3 [134]
Doxorubicin/curcumin co-loaded alginate-shelled nanodroplets - - Inhibited tumor growth In vitro
In vivo
A2780 [135]
Boron-curcumin complex 6 mg - Enhancement of anticancer effects of curcumin In vitro IGROV-1 [136]
Curcumin-loaded NLC
30 μM for 24 hours PARP, caspase-3 Apoptosis induction In vitro A2780 [137]
Curcumin-loaded δ-T3 nanoemulsion 1.96 ± 0.37 mg/ml NF-κB Anti-proliferative effects
Apoptosis induction
In vitro OVCAR-8 [138]
Bisdemethoxycurcumin 15 μM for 24 hours MMP-2, -9
CD147, uPA, ICAM-1, VCAM-1, TIMP-1, NF-κB p65, VEGF
Inhibited growth, adhesion and motility of tumor cells
Arrested cell cycle
Anti-migration and anti-invasion effects
Antioxidant effects
In vitro SKOV-3 [139]
Monofunctional platinum (II) tris (quinoline) chloroplatinum (II) 60 to
200 μM for 72 hours
- Greater toxicity on resistant tumor cells compared to cisplatin In vitro A2780 [140]
ASA/Cur-coloaded mPEG-PLGA nanoparticles 5 μg/mL Caspase-3, -9
Bcl-2, Bax
Apoptosis induction
The co-delivery of curcumin enhanced its antitumor activity
In vitro ES-2, SKOV3 [141]
Curcumin and platinum-loaded micelles 1 mg - The co-delivery of curcumin enhanced its antitumor activity In vitro A2780 [142]
MPEG-PCL curcumin micelles 5 μg/mL - Induced cell cycle arrest and apoptosis In vitro A2780 [143]
Monofunctional platinum (II) complex tris (benzimidazole) chloroplatinum (II) 180 mg - Synergistic anticancer effects on cisplatin-resistant cancer cells In vitro A2780 [144]
Co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles 20 μM
25 mg/kg
Annexin V Apoptosis induction In vitro
In vivo
PEG-PE/vitamin E micelles for co-delivery of paclitaxel and curcumin 10 μM25 mg/kg - Showed synergistic effects compared to curcumin or paclitaxel alone against cancer cells In vitro
In vivo
SK-OV-3 [146]
Curcumin loaded poly(2-hydroxyethyl methacrylate) nanoparticles 10 μg/ml NFkB, survivin, VEGF, COX-2 Anti-proliferative effectsNecrosis induction In vitro SK-OV-3 [147]
(1E, 4E)-1, 5-bis (2-methoxyphenyl) penta-1, 4-dien-3-one
10 μM for 12 hours ER stress, UPR Inhibited autophagy
Apoptosis induction
In vitro HO8910 [148]
Curcumin encapsulated Poloxamer 407/TPGS mixed micelles - P-gp Increased cytotoxicity against multidrug resistant ovarian cancer cells In vitro NCI/ADR-RES [149]